Publications by authors named "F Journe"

Claim this Profile
and validation studies of optimized iron oxide nanoparticles carrying targeting ligands for a new therapeutic strategy in head and neck cancers.
Sonia Furgiuele, Thomas Gevart, Barbara Freis, Maria Los Angeles Ramirez, Géraldine Descamps, Fabrice Journe

Nanoscale Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Potential of Glutaminase Inhibition Targeting Metabolic Adaptations in Resistant Melanomas to Targeted Therapy.
Laura Soumoy, Aline Genbauffe, Dorianne Sant'Angelo, Maude Everaert, Léa Mukeba-Harchies, Fabrice Journe

Int J Mol Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Approaches with Iron Oxide Nanoparticles to Induce Ferroptosis and Overcome Radioresistance in Cancers.
Dorianne Sant'Angelo, Géraldine Descamps, Valentin Lecomte, Dimitri Stanicki, Sébastien Penninckx, Fabrice Journe

Pharmaceuticals (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Retracted] Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles.
Philippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, Ahmad Awada, Ghanem Ghanem, Fabrice Journe

Int J Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Expression of Concern: The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
Hichame Id Boufker, Laurence Lagneaux, Mehdi Najar, Martine Piccart, Ghanem Ghanem

BMC Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis